3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other solid neoplasm
1
Conditions
Solid Tumors
1
Lymphoma, Non-Hodgkin
1
Lymphoma, Mantle-Cell
1
Lymphoma, Large B-Cell, Diffuse
1
Lymphoma, Follicular
1
Advanced Solid Tumor
1
Interventions
Injections
24
pembrolizumab
13
toripalimab
12
tislelizumab
9
Gemcitabine
7
Cisplatin
7
Carboplatin
6
atezolizumab
5
Nivolumab
5
Irinotecan
5
Pemetrexed
4
Oxaliplatin
4
Leucovorin
4
Fluorouracil
4
Docetaxel
4
Cetuximab
4
trastuzumab deruxtecan
3
spartalizumab
3
cediranib
3
Paclitaxel
3
PM 01183
3
Capecitabine
3
sintilimab
2
olaparib
2
lenvatinib
2
glumetinib
2
camrelizumab
2
apatinib
2
Therapeutics
2
Midazolam
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced Solid Tumor
×
Appointments and Schedules
×
Clear all
NCT06560632
2026-01-16
POLAR
Repare Therapeutics
Phase 1
Terminated
26 enrolled
14 charts